Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 26

1.

Estimating the Costs of Therapy in Patients with Relapsed and/or Refractory Multiple Myeloma: A Model Framework.

Roy A, Kish JK, Bloudek L, Siegel DS, Jagannath S, Globe D, Kuriakose ET, Migliaccio-Walle K.

Am Health Drug Benefits. 2015 Jun;8(4):204-15.

2.

Economic considerations for mid-urethral sling procedures among patients with stress urinary incontinence.

Roy S, Bramley TJ, Hinoul P, Migliaccio-Walle K, Li H.

J Long Term Eff Med Implants. 2013;23(1):1-8.

PMID:
24266438
3.

Management options for children with attention-deficit/hyperactivity disorder: a regional perspective on value.

Ollendorf DA, Migliaccio-Walle K, Colby JA, Pearson SD.

J Comp Eff Res. 2013 May;2(3):261-71. doi: 10.2217/cer.13.13.

PMID:
24236625
4.

Long-term patterns of use and treatment failure with anticholinergic agents for overactive bladder.

Chancellor MB, Migliaccio-Walle K, Bramley TJ, Chaudhari SL, Corbell C, Globe D.

Clin Ther. 2013 Nov;35(11):1744-51. doi: 10.1016/j.clinthera.2013.08.017. Epub 2013 Oct 3.

5.

Lopinavir/ritonavir versus darunavir plus ritonavir for HIV infection: a cost-effectiveness analysis for the United States.

Simpson KN, Pei PP, Möller J, Baran RW, Dietz B, Woodward W, Migliaccio-Walle K, Caro JJ.

Pharmacoeconomics. 2013 May;31(5):427-44. doi: 10.1007/s40273-013-0048-3.

PMID:
23620210
6.

Anticoagulation prophylaxis in orthopedic surgery: an efficiency frontier approach.

Migliaccio-Walle K, Rublee D, Simon TA.

Postgrad Med. 2012 Jan;124(1):41-9. doi: 10.3810/pgm.2012.01.2516.

PMID:
22314113
7.

Evaluation of the consequences associated with diffuse vascular disease history in patients diagnosed with peripheral arterial disease: estimates from Saskatchewan health data.

Migliaccio-Walle K, Stokes M, Proskorovsky I, Popovici-Toma D, El-Hadi W.

BMC Cardiovasc Disord. 2010 Sep 2;10:40. doi: 10.1186/1471-2261-10-40.

8.

Cost effectiveness of deferasirox compared to desferrioxamine in the treatment of iron overload in lower-risk, transfusion-dependent myelodysplastic syndrome patients.

Tolley K, Oliver N, Miranda E, Migliaccio-Walle K, Bozkaya D, Li Q.

J Med Econ. 2010;13(3):559-70. doi: 10.3111/13696998.2010.516203.

PMID:
20812793
9.

NICE cost-effectiveness appraisal of cholinesterase inhibitors: was the right question posed? Were the best tools used?

Getsios D, Migliaccio-Walle K, Caro JJ.

Pharmacoeconomics. 2007;25(12):997-1006. Review.

PMID:
18047386
10.

Economic implications of growth hormone use in patients with short bowel syndrome.

Migliaccio-Walle K, Caro JJ, Möller J.

Curr Med Res Opin. 2006 Oct;22(10):2055-63.

PMID:
17022865
11.

The time course of subsequent hospitalizations and associated costs in survivors of an ischemic stroke in Canada.

Caro JJ, Migliaccio-Walle K, Ishak KJ, Proskorovsky I, O'Brien JA.

BMC Health Serv Res. 2006 Aug 14;6:99.

12.

Economic implications of extended-release metoprolol succinate for heart failure in the MERIT-HF trial: a US perspective of the MERIT-HF trial.

Caro JJ, Migliaccio-Walle K, O'Brien JA, Nova W, Kim J, Hauch O, Hillson E, Wedel H, Hjalmarson A, Gottlieb S, Deedwania PC, Wikstrand J; MERIT-HF Study Group.

J Card Fail. 2005 Dec;11(9):647-56.

PMID:
16360958
13.

Costs and medical care consequences associated with the diagnosis of peripheral arterial disease.

Migliaccio-Walle K, Caro JJ, Ishak KJ, O'Brien JA.

Pharmacoeconomics. 2005;23(7):733-42.

PMID:
15987229
14.

The morbidity and mortality following a diagnosis of peripheral arterial disease: long-term follow-up of a large database.

Caro J, Migliaccio-Walle K, Ishak KJ, Proskorovsky I.

BMC Cardiovasc Disord. 2005 Jun 22;5:14.

15.

Estimating survival for cost-effectiveness analyses: a case study in atherothrombosis.

Caro JJ, Ishak KJ, Migliaccio-Walle K.

Value Health. 2004 Sep-Oct;7(5):627-35.

PMID:
15367257
16.

Comparing medications in a therapeutic area using an NNT model.

Caro JJ, Ishak KJ, Caro I, Migliaccio-Walle K, Klittich WS.

Value Health. 2004 Sep-Oct;7(5):585-94.

PMID:
15367253
17.

Assessing the health and economic impact of galantamine treatment in patients with Alzheimer's disease in the health care systems of different countries.

Caro J, Salas M, Ward A, Getsios D, Migliaccio-Walle K, Garfield F.

Drugs Aging. 2004;21(10):677-86.

PMID:
15287825
18.

Rational choice of cholinesterase inhibitor for the treatment of Alzheimer's disease in Canada: a comparative economic analysis.

Caro J, Getsios D, Migliaccio-Walle K, Ishak J, El-Hadi W; AHEAD Study Group.

BMC Geriatr. 2003 Dec 15;3:6.

19.

Economic evaluation of galantamine in the treatment of mild to moderate Alzheimer's disease in the United States.

Migliaccio-Walle K, Getsios D, Caro JJ, Ishak KJ, O'Brien JA, Papadopoulos G; AHEAD Study Group.

Clin Ther. 2003 Jun;25(6):1806-25.

PMID:
12860500
20.

To what degree does cognitive impairment in Alzheimer's disease predict dependence of patients on caregivers?

Caro J, Ward A, Ishak K, Migliaccio-Walle K, Getsios D, Papadopoulos G, Torfs K.

BMC Neurol. 2002 Aug 19;2:6.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk